First Live Births With A Novel Simplified IVF Procedure
Cambridge, UK, February 4, 2014
prospective study published in Reproductive BioMedicine Online comparing conventional IVF with a novel
simplified laboratory method of culturing embryos suggested that fertilization
and implantation rates were similar for the simplified system when compared
with those reported by conventional IVF programs. Sixteen healthy babies have
already been born with this new method. According to the results of this study,
IVF may be offered at a more reasonable price and made available to a larger
part of the world population. Other quality studies are needed to determine the
reduction in cost and the prospect of different patient groups using this
More than 5 million IVF babies have now been born worldwide, but because of high costs IVF is largely the preserve of developed countries and is only available or affordable for less than 10% of the world population. The success and sustainability of assisted reproductive technologies will depend to a large extent on the ability to optimise these techniques in terms of availability, affordability and effectiveness.
In developing countries the consequences of involuntary childlessness can create wide-ranging societal problems, especially for women. Because many families in developing countries depend entirely on children for economic survival, childlessness can often be viewed as a social and public-health issue and not only as a medical problem.
Published in Reproductive BioMedicine Online, American and Belgian researchers outline the first results of a prospective study performed in Genk, Belgium. They report the results of a study in which a simple, reduced cost IVF culture system was used to replace more expensive incubator systems. The new method does not alter the need for surgical egg retrieval and embryo transfer, laboratory staffing and egg or embryo freezing.
In a short prospective clinical trial, successful outcomes were obtained with the simplified method at levels that compare favourably with those reported by typical IVF programs in developed countries.
Sixteen healthy babies have now been born using the new method. It is expected that laboratory costs may be reduced, however the extent of this remains to be determined.
The simplified IVF method has the potential to open up a new era in the history of IVF and may not only change the accessibility of IVF in resource-poor countries, but also have implications for accessibility in developed countries too, where IVF is increasingly becoming available only to affluent couples. The trend in IVF has been to introduce new and complex instruments and tests. It is hoped that the new embryo culture method may change this philosophy.
This study is part of the Walking Egg Project (www.thewalkingegg.com), an international project that aims to raise awareness surrounding involuntary childlessness in resource-poor countries. The project also aims to make infertility care in all its aspects, including assisted reproductive technologies, available and accessible for a larger proportion of the world population in both developing and developed countries.
The research papers presenting the results of this prospective study on the novel simplified method of embryo culture process are:
Van Blerkom, J., Ombelet, W., Klerkx, E., Janssen, M., Dhont, N., Nargund, G.,Campo, R. First births with a simplified culture system for clinical IVF and embryo transfer. (doi: 10.1016/j.rbmo.2013.11.012). The article appears in Reproductive BioMedicine Online, in Press, published by Elsevier.
Ombelet, W. 2013. Is global access to infertility care realistic? The Walking Egg Project. (doi: 10.1016/j.rbmo.2013.11.013). The article appears in Reproductive BioMedicine Online, in Press, published by Elsevier.
# # #
Notes for editors
Full text of the research papers available to credentialed journalists upon request; contact email@example.com. Journalists wishing to interview the authors may contact Greyling Peoples at +31 20 485 3323 or firstname.lastname@example.org.
About Reproductive BioMedicine Online
Reproductive BioMedicine Online was founded by Bob Edwards, the winner of the 2010 Nobel Prize in Physiology or Medicine. It covers the formation, growth and differentiation of the human embryo. It is intended to bring to public attention new research on biological and clinical research on human reproduction and the human embryo including relevant studies on animals. It is published by a group of scientists and clinicians working in these fields of study. Its audience comprises researchers, clinicians, practitioners, academics and patients.
It is the Official journal of AAB College of Reproductive Biology (CRB), Alpha (Scientists in Reproductive Medicine), American College of Embryology (ACE), the Global Chinese Association for Reproductive Medicine (GCARM), International Society for Fallopian Tubes and Reproductive Surgery (ISFT-RS), the International Society for In Vitro Fertilization (ISIVF), the Mediterranean Society for Reproductive Medicine (MSRM), the Preimplantation Genetic Diagnosis International Society (PGDIS) and the Turkish Society of Reproductive Medicine (TSRM). www.rbmojournal.com
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 3323